1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 14 MARCH 2016

Cancer Drug News 14 MARCH 2016

  • March 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Towards Harmonising Transatlantic Review Times
Industry Trend Analysis - Zydelig Woes Underscore Need For Scale-Up In Diversification Efforts
Industry Brief - FDA Grants ODD To ProNAi's PNT2258 For DLBCL
Industry Brief - Variation To Arzerra Marketing Authorisation Filed With EMA
Industry Brief - DSMB Recommends Advancing Medigene's DC AML Vaccine To Phase II
Industry Brief - Pfizer's Xalkori Granted FDA Approval For ROS1-Positive Metastatic NSCLC
Industry Brief - Imbruvica FDA-Approved For First-line Treatment Of CLL
Industry Brief - FDA Accepts Keytruda sBLA In Advanced NSCLC
Industry Brief - FDA ODD For Soricimed's SOR-C13 To Treat Ovarian Cancer
Industry Brief - XBiotech Submits Xilonix MAA In EU To Treat Advance CRC
Industry Brief - DSMB Recommends Discontinuation Of Celldex' Rintega Phase III Study In Glioblastoma
Industry Brief - Lenvima Launched In Israel To Treat Advanced Thyroid Cancer
Industry Trend Analysis - USD999 Whole Genome Sequencing Will Challenge Single Biomarker Tests
Industry Trend Analysis - Growing Cancer Burden Will Boost Revenue Earning Opportunities
Industry Brief - Aprea Completes Fundraising To Advance APR-246 Clinical Development
Industry Brief - Aspyrian Secures Series B Funding

Table Of Contents

Cancer Drug News 14 MARCH 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.